spacer
home > epc > autumn 2003 > industry trends in the development and provision of 21 cfr part 11-compatible equipment
PUBLICATIONS
European Pharmaceutical Contractor

Industry Trends in the Development and Provision of 21 CFR Part 11-Compatible Equipment

Background

The FDA's 21 CFR Part 11 has been in effect since August 1997. Part 11 establishes the standards for ensuring electronic records and electronic signatures are as trustworthy and reliable as paper records and handwritten signatures. The regulation 'applies to records in electronic form that are created,

modified, archived, retrieved or transmitted under any records requirements' (1) as set forth by a predicate rule. Predicate rules include any requirements set forth by any FDA regulation, such as good laboratory practice (GLP), good manufacturing practice (GMP) and good clinical practice (GCP).

In the years following the introduction of Part 11, as industry began to attempt to comply with its requirements, the implications and broad scope of the rule became apparent. Pharma companies were expected to be making progress towards compliance with Part 11 by:
Assessing their current systems against the requirements
Determining the actions needed for each system to attain compliance
Developing procedural and technical controls
Generating and executing validation and implementation plans


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Lynda Bruce, Principal Engineer in the Life Sciences Business Unit and Annie Broadhurst, Technical Scholar at Cambridge Consultants Ltd

Dr Lynda Bruce is a Principal Engineer in the Life Sciences Business Unit at Cambridge Consultants Ltd where she specialises in regulatory issues affecting process and product development. Lynda joined CCL from Integral Inc, a management consulting firm, where she focused on organisational and strategy issues for clients in the pharmaceutical industry. She has also worked for Wardrop Engineering as a Process Engineer and for Hemosol Inc as a Process Development Engineer.

Annie Broadhurst is a Technical Scholar at Cambridge Consultants Ltd. She also studies Pharmacology at the University of Manchester.

spacer
Dr Lynda Bruce
spacer
spacer
spacer
Annie Broadhurst
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement